Summit Therapeutics to Showcase Ivonescimab Pipeline at March Investor Conferences — Summit Therapeutics Inc.

Event summary

Summit Therapeutics will present at three investor conferences in March 2026, including fireside chats on March 2 and March 11.
The company is focusing on its lead candidate ivonescimab, a bispecific antibody targeting PD-1 and VEGF, with multiple Phase III trials underway.
Summit has submitted a BLA for ivonescimab in NSCLC, with a PDUFA date of November 14, 2026.
Ivonescimab has shown promising results in over 4,000 patients globally and 60,000 in China.

The big picture

Summit Therapeutics is positioning itself as a key player in the biopharmaceutical oncology space, leveraging its partnership with Akeso Inc. to advance ivonescimab through multiple Phase III trials. The upcoming investor conferences provide an opportunity for the company to highlight its clinical pipeline and regulatory progress, particularly following the FDA's acceptance of its BLA submission for ivonescimab in NSCLC.

What we're watching

Regulatory Timeline: Whether the FDA will meet the November 2026 PDUFA date for ivonescimab's BLA submission.
Clinical Pipeline Expansion: The pace at which Summit can advance its Phase III trials in NSCLC and CRC, following positive readouts from Akeso's studies.
Market Differentiation: How ivonescimab's unique bispecific design will position it against existing PD-1 and VEGF inhibitors in the oncology market.